Featured Articles

Developing a Topical Adjunct to Injectable Procedures

By June 24, 2020July 1st, 2020No Comments

Dermatology News

Featured Article

“In vivo testing of bruising resolution demonstrated that at day 2/3, participants using the study product (INhance Post-Injection Serum with TriHex Technology®, Alastin Skincare, Inc. Carlsbad, CA) had 73% less bruise color intensity and statistically significant improvement over the bland moisturizer. “

Read Article Now

Developing a Topical Adjunct to Injectable Procedures

New JDD study reveals 81% of subjects applying a topical product had less bruising at day 2/3 compared to the bland moisturizer.

Injectable procedures have come to play an enormous part in everyday  aesthetic medical practice. Whether its use is directed at volumizing with fillers, decreasing volume using enzymes, skin-tightening using multi-needle approaches, or neuromuscular blockade, the injectable route is the means of delivery in all these cases, making injectable procedures the most common aesthetic procedure performed.

As with all procedures, expected and unexpected consequences may follow including bruising, swelling, discomfort, and the possibility of infection. This paper outlines the scientific process and validation of a product designed as an adjunct to injection therapy and the scientific deep dive needed to encompass both symptomatic and adjunctive purposes. On the symptomatic side, bruising, swelling, and pain were considered, while volumetric enhancement, regeneration, and anti-microbial/biofilm effects were desired outcomes from the adjunctive perspective.

Utilizing peptides and active agents aimed at reducing excess residual iron and stimulating macrophage absorption of red blood cells, we were able to achieve efficient resolution of bruising. In addition, peptides were included to stimulate collagen, elastin, and hyaluronic acid in synergy with the injectable. Anti-inflammatory, antimicrobial, and antibiofilm agents were added to aid in the safety profile of the injectable.

In vivo testing of bruising resolution demonstrated that at day 2/3, participants using the study product (INhance Post-Injection Serum with TriHex Technology®, Alastin Skincare, Inc. Carlsbad, CA) had 73% less bruise color intensity and statistically significant improvement over the bland moisturizer. Overall, 81% of subjects applying the study topical product had less bruising at day 2/3 compared to the bland moisturizer.

Read Article Now
JDD Article Referenced in this Post

You May Also Like

Journal of Drugs in Dermatology JDD Article About Understanding Topical Steroid Withdrawal: Where Are We Now?

Understanding Topical Steroid Withdrawal: Where Are We Now?

| Featured Articles, Latest News, Medical Derm, The Latest | No Comments
Topical Steroid Withdrawal — What Your Patients Are Watching Online Topical steroid withdrawal (TSW) is an increasingly visible — and misunderstood — drug‑related dermatosis that can follow abrupt discontinuation of…
Journal of Drugs in Dermatology JDD Article About Beyond Inflammation and Itch: A Call for a Broader Framework in Atopic Dermatitis

Beyond Inflammation and Itch: A Call for a Broader Framework in Atopic Dermatitis

| Atopic Dermatitis, Featured Articles, Latest News, The Latest | No Comments
Rethinking AD — Beyond Inflammation  Atopic dermatitis remains common and stubborn, especially in pediatric patients, because inflammation is only one part of a self‑reinforcing loop that includes microbiome disruption, neuroimmune…
Journal of Drugs in Dermatology JDD introducing new Editorial Board Member: Dr. Theodore (Ted) Daly, also highlighting his article Telogen Effluvium With Dysesthesia (TED) Has Lower B12 Levels and May Respond to B12 Supplementation

JDD Welcomes Our Newest Editorial Board Member

| Featured Articles, Latest News, The Latest | No Comments
Meet Dr. Theodore (Ted) J. Daly Theodore (Ted) J. Daly MD has been in private practice at Garden City Dermatology, New York, for nearly four decades. He received his medical…

Leave a Reply